OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.

OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.

OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.

PFE aims to break into the obesity market with berobenatide, a potential monthly treatment designed to compete with leading GLP-1 therapies.

Several stocks have recently seen notable insider buys from CEOs, including a $10 million dollar bet from a semiconductor favorite.

Bristol Myers wins FDA accelerated approval for Zenbexus, the first CELMoD therapy, as data show it doubles MRD-negative complete response rates.

Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.

PFE's non-COVID products are gaining momentum, with launches, acquisitions and a pipeline aimed at driving growth from 2029 onward.

BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled, fueling growth and pipeline advances.

Pfizer's Q2 beat and raised 2026 revenue outlook signal progress, but declining COVID sales and patent losses challenge its growth path.